Project Context and Objectives:
Gene delivery represents a fundamental challenge in modern biotechnology and therapeutic development, with applications ranging from basic research to advanced cell therapies. The ability to efficiently introduce genetic material into cells is essential for developing treatments for genetic diseases, cancer immunotherapies, and regenerative medicine approaches. However, current gene delivery methods present significant limitations that hinder both research progress and clinical translation.
Present Challenges and Unmet Needs:
Lentiviruses currently serve as the standard solution for achieving workable transduction efficiencies across diverse cell types. While these viral vectors are effective, they create permanent and random integration into the host cell's genome, which raises significant safety concerns, including the potential for DNA damage and an increased cancer risk. This permanent genetic modification poses significant challenges for therapeutic applications, where transient expression is typically preferred. Alternative non-viral approaches, such as lipid nanoparticles (LNPs), offer improved safety profiles but suffer from limited efficacy, particularly in hard-to-transfect cell types, including differentiated human induced pluripotent stem cells (hiPSCs), post-mitotic cortical neurons, and T cells.
Project Innovation and Objectives:
To address these critical limitations, we have developed VLPs as a genetically controlled, biogenic RNA delivery vehicles that combine the high efficacy of viral systems with the safety advantages of non-viral approaches. We have developed a set of ready-to-use, R&D-grade VLP solutions that can effectively target complex cell types while maintaining Biological Safety Level 1 (BSL-1) safety standards. As a key addition to our RNA delivery capabilities, we have demonstrated that our VLP platform can package CRISPR effectors as ribonucleoprotein complexes (RNPs) for precise gene editing applications. This approach will deliver significant advantages over traditional CRISPR delivery methods by providing a controlled, finite editing time window while eliminating the permanent expression of potentially immunogenic CRISPR components. The transient nature of our RNP delivery system is expected to reduce off-target effects and immune responses, making it particularly suitable for therapeutic applications where precision and safety are paramount.
The anticipated impact and significance:
The VLP technique provides laboratories with enhanced tools for targeting challenging-to-transfect cells, including therapeutic cells. This technology has the potential to accelerate research timelines, reduce experimental costs, and facilitate a safer transition of genetic therapies to clinical use. This advancement has the potential to influence gene delivery approaches, possibly contributing to the development of therapies with improved safety profiles.
